Exelixis Inc. (EXEL)
Exelixis: Stock Likely To Go Higher On A Possible Key FDA Approval
Exelixis offers strong growth potential, trading at 14x 2026E EPS, below sector median, with robust oncology franchises and disciplined R&D spending. Cabozantinib remains the near-term growth driver, while zanzalintinib is positioned as the next major oncology franchise, targeting $5B in annual revenue by 2033. EXEL delivered 2025 revenue of $2.32B (+7% YoY), with net product revenue up 17% and margin expansion supporting a projected 17% EPS growth for 2026.
EXEL vs. EXAS: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or Exact Sciences (EXAS). But which of these two stocks offers value investors a better bang for their buck right now?
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Exelixis: High-Growth Oncology Name Trading At A Discount
Exelixis offers exceptional medium-term growth, driven by Cabometyx's market leadership and a robust pipeline, yet remains undervalued versus peers. EXEL maintains high profitability and growth without debt, aggressively repurchasing shares and tightly controlling costs to sustain margins. Management is diversifying revenue with new drugs, notably zanzalintinib, while proactively addressing single-product risk and optimizing R&D efficiency.
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report?
Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Exelixis, Inc. (EXEL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Exelixis, Inc. (EXEL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Exelixis Posts Preliminary '25 Results, Issues '26 Outlook
EXEL posts approximately $2.32B in 2025 revenues and guides $2.525 -$2.625B for 2026 as Cabometyx grows and a zanzalintinib NDA advances.
Here's Why Exelixis (EXEL) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
EXEL Collaborates With Natera for Late-Stage Colorectal Cancer Study
Exelixis teamed with Natera on the phase III STELLAR-316 study testing zanzalintinib in resected stage II/III colorectal cancer. Stock gains.
See How Rare Bullish Inflows Lift Outliers Like Exelixis
Exelixis, Inc. (EXEL), an oncology-focused biopharmaceutical firm, is up 81% since a Big Money boost starting in 2021.
Here's Why Exelixis (EXEL) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
